Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Autolus Therapeutics plc ADR shares valued at $2,955,674 were purchased by Martin Pule on Sep 16 ’24. At $4.23 per share, Martin Pule acquired 698,741 shares.
As published in a research note from Goldman on November 18, 2024, Autolus Therapeutics plc ADR [AUTL] has been rated up from a Neutral to a Buy and the price target has been revised to $7.60 from $7. Analysts at Redburn Atlantic upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in mid November. As of November 09, 2023, Deutsche Bank has initiated its “Buy” rating for AUTL.
Analyzing AUTL Stock Performance
During the last five days, there has been a drop of approximately -4.55%. Over the course of the year, Autolus Therapeutics plc ADR shares have dropped approximately -10.64%. Shares of the company reached a 52-week high of $2.80 on 01/03/25 and a 52-week low of $2.07 on 02/04/25. A 50-day SMA is recorded $2.51, while a 200-day SMA reached $3.60. Nevertheless, trading volume fell to 1.34 million shares from 1.34 million shares the previous day.
Support And Resistance Levels for Autolus Therapeutics plc ADR (AUTL)
According to the 24-hour chart, there is a support level at 2.05, which, if violated, would cause prices to drop to 2.00. In the upper region, resistance lies at 2.19. The next price resistance is at 2.27. RSI (Relative Strength Index) is 39.01 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.06, which suggests the price will decrease in the coming days. Percent R is at 91.67%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
